PubMed · 2008 · 20 citations · 7 references
MedicineGeneticsOncologyCancer GeneticsMolecular OncologyOncogenesOncogene AmplificationPancreatic CancerTranscription Factor OncogenesAmplification-driven TumorigenesisBrca2 FunctionBrca2 InactivationDna In Situ HybridizationFamilial Pancreatic CancerMicroarray AnalysisOncogene Expression AnalysisTissue Microarray Analysis
Mutations in the breast cancer susceptibility gene 2 (BRCA2) are commonly found in familial pancreatic cancer. Recently, EMSY (11q13.5) has been described as a BRCA2 interacting protein capable of binding and inactivating the protein domain encoded by exon 3 of the BRCA2 gene. Amplification of EMSY occurs in 13% of sporadic breast cancers and is directly linked to increased expression. Here we investigate the amplification status of this new potential oncogene in 59 sporadic pancreatic cancers using fluorescence in situ hybridization (FISH) and tissue microarray (TMA). Real-time quantitative RT-PCR was performed on 20 pancreatic cancer cell lines and overexpression was calculated using the delta-delta-Ct-method. Amplification of EMSY was found in 8/59 cases (13.6%). 9/20 (45%) cell line samples showed overexpression of EMSY. In conclusion, sporadic pancreatic cancer shows amplification of EMSY at prevalence similar to that found in other cancers.
7
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.
Michael Goggins, Mieke Schutte, Jing Lü et al. · PubMed · 1996 · 648 citations
Hypermethylation of multiple genes in pancreatic adenocarcinoma.
Takashi Ueki, Minoru Toyota, Taylor A. Sohn et al. · PubMed · 2000 · 408 citations
The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma.
Metin Tascilar, Halcyon G. Skinner, Christophe Rosty et al. · PubMed · 2001 · 310 citations
Fanconi anemia gene mutations in young-onset pancreatic cancer.
Michiel S. van der Heijden, Charles J. Yeo, Ralph H. Hruban et al. · PubMed · 2003 · 264 citations
Life Sciences, Genetics, Oncology +14